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Background. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly spread worldwide from the
beginning of 2020. Quantitative reverse transcription-PCR (RT-qPCR) is, to this day, the preferred methodology for viral RNA
detection, even if not without problems. To overcome some of the limitations still existing for the detection and quantification
of nucleic acids in various applications, the use of one-step reverse transcription-droplet digital PCR (RT-ddPCR) has been
established. The purpose of this study was, then, to evaluate the efficacy of ddPCR for the detection of SARS-CoV-2 RNA in
nasopharyngeal swabs, optimizing the detection of low-viral load-burdened samples. Methods. The RT-ddPCR workflow was
validated for sensitivity, specificity, linearity, reproducibility, and precision using samples from 90 COVID-19-infected patients
referred to the Department of Laboratory Medicine of the University Hospital of Udine (Italy). Results. The present study shows
that RT-ddPCR allows the detection of as low as 10.3 copies of a SARS-COV-2 E-gene per sample with a higher level of
accuracy and precision, especially at low concentration. Conclusion. During the postpeak phase of the SARS-CoV-2 pandemic, it
is essential to rely on a highly robust molecular biology method to identify infected subjects, whether they have symptoms or
not, in order to prepare appropriate containment measures.
1. Introduction
The emergence of severe acute respiratory syndrome corona-
virus 2- (SARS-CoV-2-) related disease (COVID-19) in
China at the end of 2019 caused a major global outbreak
and still represents a serious public health issue. Indeed,
towards the end of January 2020, the World Health Organi-
zation (WHO) declared COVID-19 as the sixth public health
emergency of international concern [1]. The so-called SARS-
CoV-2 is a single-stranded RNA virus belonging to the genus
Betacoronavirus. Multiple sequence alignments revealed that
SARS-CoV-2 is closely related to bat-derived SARS-like cor-
onaviruses (88–89% similarity), but when compared to
severe acute respiratory syndrome coronavirus (SARS-
CoV) and Middle East respiratory syndrome coronavirus
(MERS-CoV), SARS-CoV-2 showed less genetic similarity
(79% and 50%, respectively) [2]. The associated disease,
called COVID-19, is characterized by fever, fatigue, dry
cough, pharyngodynia, shortness of breath, headache, chest
tightness, chest pain, and myalgia [3]. In some patients, the
symptomatology worsens rapidly leading to acute respiratory
distress syndrome (ARDS) [4]. A variable proportion of
infected subjects, estimated to be around 20–25%, does not
show any symptoms, making it difficult to limit the infection,
since these patients are capable to spread the virus and may
represent a population that can be easily neglected in the pre-
vention of epidemics. Indeed, public health authorities would
need to implement rapid and sensitive diagnostic tools for
patients’ management in the shortest possible time. Accord-
ing to the World Health Organization (WHO), the current
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gold standard for the diagnosis of SARS-CoV-2 infection is
based on quantitative reverse transcription-PCR (RT-qPCR),
which can detect SARS-CoV-2 nucleic acid patient samples.
Droplet digital PCR (ddPCR) is a variant of the
emulsion-based PCR technology. It is a promising, ultrasen-
sitive approach, capable of compartmentalizing samples into
millions of picoliter droplets containing single-nucleic acid
(NA) molecules and analyzing the terminal fluorescence of
each droplet after parallel amplification [5]. Moreover, it
eliminates the need for a standard curve as for quantitative
PCR (qPCR) [5, 6]. This cutting-edge technology has quickly
entered into clinical practice, providing useful indications for
prognostic evaluation, monitoring, and characterization of
diseases but also for the detection of nucleic acids of patho-
gens [7, 8]. Furthermore, several data on the development
of the reverse transcription-ddPCR (RT-ddPCR) method
have been produced, demonstrating that this technique has
a higher precision and improved sensitivity to detect rare tar-
gets at low copy numbers than RT-qPCR.
During the postpeak phase of the SARS-CoV-2 pan-
demic, it is mandatory to rely on a highly robust molecular
biology technique to detect infected subjects, whether symp-
tomatic or not, to set up appropriate containment measures.
The aim of this study was to validate and optimize the detec-
tion of low-viral load-burdened patients coupling the already
available primers and probe sets and the RT-ddPCR tech-
nique, identifying the most suitable workflow.
2. Materials and Methods
2.1. Patient Samples. SARS-CoV-2 samples were collected
from 90 symptomatic, paucisymptomatic, or asymptomatic
patients by nasopharyngeal swab, referred to the Department
of Laboratory Medicine, University Hospital of Udine, Italy,
and reported to be positive by standard molecular biology
procedures (RT-qPCR). For swab collection, transportation,
and long-term storage, UTM® tubes (COPAN Diagnostics)
were used, according to manufacturer’s instructions. Ethical
approval was obtained from the Medical Research Ethics
Committee of the Region Friuli Venezia Giulia, Italy (Con-
sent CEUR-2020-Os-033).
2.2. RNA Extraction from Nasopharyngeal Swab. For the
automatic extraction with the ELITe InGenius® SP200 (ELI-
TechGroup) system of SARS-CoV-2 RNA, 200μL of the
medium from UTM® tubes containing 3mL was used, fol-
lowing the manufacturer’s instructions. Samples were eluted
in 100μL elution buffer and used as the template for down-
stream analysis. Extracted RNA was stored at −80°C.
2.3. One-Step Reverse Transcription-Droplet Digital
Polymerase Chain Reaction (RT-ddPCR). 5′6-FAM/3′BHQ-
1®-conjugated assays were used for viral load assessment by
the One-Step RT-ddPCR Advanced Kit for Probes (Bio-
Rad). Oligonucleotides are listed in Table 1 and were pur-
chased from Merck KGaA. Briefly, 5μL of ddPCR™ Super-
mix for Probes (No dUTP), 900nM primers and 250nM
probes, 15mM DTT, 20U/μL reverse transcriptase, 2μL
sample, and nuclease-free water were mixed in a total volume
of 20μL. Samples were mixed with Droplet Generator Oil for
Probes (Bio-Rad) and droplets were generated with the auto-
mated droplet generator QX200™ droplet generator (Bio-
Rad). PCR amplification was performed on the Veriti® Ther-
mal Cycler (Thermo Fisher Scientific). Amplification was
performed at 50°C for 60min for reverse transcription,
95°C for 10min for enzyme activation, and followed by 45
cycles of 95°C for 30 s, 55°C for 60 s, and then 98°C for
10min for enzyme deactivation. Droplets were read on the
QX200™ droplet reader (Bio-Rad) and reactions with less
than 10,000 droplets were repeated. Primers and the 5′
HEX/3′ BHQ-1®-conjugated probe for RNaseP human gene
were evaluated to verify the adequacy of RNA isolation. Data
were analyzed using the QuantaSoft™ 1.7.4 Software (Bio-
Rad). For all experiments in this work, the same thresholds
were used for FAM and HEX signals. These were determined
by running in a multiplex positive control (lyophilized posi-
tive control from the LightMix® Modular SARS and Wuhan
CoV E-gene from Roche) and no template control samples.
2.4. Quantitative Reverse Transcription-Polymerase Chain
Reaction (RT-qPCR). To detect viral RNA, LightMix® Modu-
lar SARS and Wuhan CoV E-gene (Roche) was used as pre-
viously described [9]. RT-qPCR was performed by the
LightCycler® 480 II Instrument (Roche) and absolute quanti-
fication was assessed by the LightCycler® 480 II System
(Roche). The estimated viral copy number extracted from
the Cq values by RT-qPCR was calculated based on the linear
regression of a serial dilution made with the synthetic control
for the E gene supplied by Roche in the LightMix® Modular
SARS and Wuhan CoV E-gene kit.
2.5. Limit of Blank (LoB) and Limit of Detection (LoD). The
Limit of Blank (LoB) and Limit of Detection (LoD) have been
evaluated to avoid false-positive and false-negative results
and to reliably and critically describe the minimum viral load
that can be detected with this method. The Limit of Blank
(LoB) has been established as the highest number of viral
copies that can be measured when no template control
(NTC) replicates are tested. The LoB was established using
the signal-to-noise ratio, i.e., by measuring false-positive
events from 40 wells of NTC for each primer and probe set
(see Table 1), using the following formula: LoB =MeanNTC
+ 1:645 ∗ SDNTC as previously described [10, 11]. The LoD
represents the lowest amount of analyte that can be reliably
detected, i.e., the lowest number of copies that can be clearly
distinguished from the background with 99% probability,
ensuring a false-positive rate ≤ 5%. In our study, the LoD
was calculated as: LoD =MeanNTC + 3 ∗ SDlow , being SDlow
the standard deviation of low-concentration samples [11–
13]. The LoB and LoD have been established for all the oligo-
nucleotides listed in Table 1.
2.6. Limit of Quantification (LoQ). The LoQ represents the
lowest amount of analyte that can be reliably quantified with
precision and accuracy. It was computed through the signal-
to-noise method as LoQ =MeanNTC + 10 ∗ SDlow. In addi-
tion, for the E gene alone, the LoQ was further validated by
7 serial dilutions (fivefold each) of a SARS-CoV-2-positive
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sample, with each dilution being repeated ten times (see Sec-
tion 2.10). The concentration that had a coefficient of varia-
tion (CV) of less than 30% was used as the LoQ [10, 14, 15].
2.7. Agreement. To evaluate the agreement between our RT-
ddPCR and the gold standard (RT-qPCR), Bland-Altman
analysis was used. A total of 60 samples were used for this
purpose, divided in 30 positive and 30 negative samples for
SARS-CoV-2. To evaluate the distribution of the data, the
Shapiro-Wilk normality test was performed. A comparison
of the methods was made using the Spearman rank correla-
tion coefficient analysis. Raw data from the analysis of posi-
tive samples with RT-qPCR and RT-ddPCR are presented
in Supplementary Table 1.
2.8. Accuracy. The accuracy of an analytical procedure is the
closeness of the test results obtained by that method to a spe-
cific value, be it the true conventional value or the accepted
reference one. The evaluation of RT-ddPCR accuracy was
performed by testing four different dilutions of a positive
sample (Cq 20.7 by RT-qPCR), with 10 replicates each. The
positive control was diluted using the buffer in which the
viral RNA was extracted in (ELITe InGenius® SP200 system).
2.9. Precision. The precision of an analytical procedure is
defined as the closeness of measurements of a series obtained
from multiple determinations of the same sample under spe-
cific conditions. It can be established as repeatability and
intermediate precision. Repeatability was assessed by evalu-
ating the variance by analyzing a positive sample at three dif-
ferent dilutions, three times on the same day, using the same
equipment and the same batch for each reagent. Intermediate
precision was assessed by measuring a positive sample at
three different dilutions, three times each day for three con-
secutive days. The distribution of each series of results was
checked with the Shapiro-Wilk test. To assess the equality
of variances, the precision was examined using the one-way
ANOVA, according to ISO 5725 guidelines [16].
2.10. Linearity. The linearity of an analytical procedure is its
ability to obtain test results that are directly proportional to
the concentration of an analyte in samples within a given
range or through well-defined mathematical transforma-
tions. The linear range of RT-ddPCR was established with a
series of 7-step dilutions. Each dilution was tested in 10 rep-
licates. The relationship between the observed values and the
gold standard was examined by linear regression.
2.11. Statistics. The statistical analysis was performed with
GraphPad Prism 6.0. Grubb’s test was used to identify the
outliers within replicates. Quantitative variables were ana-
lyzed with one-way ANOVA. A p value≤ 0.05 was consid-
ered statistically significant. ∗p < 0:05, ∗∗p < 0:01,
∗∗∗p < 0:001, and ∗∗∗∗p < 0:0001.
3. Results
We optimized a RT-ddPCR workflow using the primer and
probe sets published in early 2020 by both the German Con-
siliary Laboratory for Coronaviruses (Charité, Berlin) [17]
and the United States Center for Disease Control and Pre-
vention (CDC, Atlanta) [18], which have been approved for
COVID-19 in vitro diagnostics. Table 1 contains information
about the six different primer pairs (named assays) used in
this study, which are directed to specific regions of the
SARS-CoV-2 genome. The Limit of Blank (LoB) was deter-
mined for all assays by analyzing 40 no template control
(NTC) replicates. All analytical points showed more than
10,000 droplets and were therefore retained for further anal-
ysis. The use of N1 assay was immediately abandoned due to
the high rate of primer dimers that create positive amplifica-
tion in all NTC replicates (data not shown). The Limit of
Detection (LoD) was then calculated for all 5 assays, as the
Table 1: Primers and probes for SARS-CoV-2 detection used in this study.



















aY is C/T, R is A/G, and S is C/G.
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mean of NTCs plus three standard deviation of low concen-
trated samples. As shown in Table 2, the assay targeting the
envelope gene (E gene) presented the lowest LoD (7 copies/-
reaction) compared to the other assays. To make sure that
the patient samples were evaluated in the best possible way,
avoiding to lose the low viral loads, we calculated the Limit
of Quantification (LoQ), and to do so, we used the assay that
evaluates the E gene since it is the one that demonstrated the
best performance (Table 2).
We then evaluated the sensitivity and specificity of all five
assays, testing 30 patient samples, (19 positives and 11 nega-
tives) with standard molecular biology techniques for the
detection of SARS-CoV-2 (i.e., RT-qPCR) [19]. With the
exception of the N2 assay, all primers and probes showed
100% specificity but a variable degree of sensitivity. Table 3
summarizes the sensitivity and specificity percentages for
all the assays evaluated.
Considering all data collected so far, we continued our
workflow validation using primers and probes for the E gene,
the assay that has shown the lowest LoQ, and the best combi-
nation of specificity and sensitivity.
The Bland-Altman analysis showed that all negative sam-
ples presented viral copies below the estimated LoQ. The bias
between the measurements was 0.168 (95% CI: 0.030-0.307)
with an agreement of 95% (Figure 1). The Shapiro-Wilk nor-
mality test showed that the population was not normally dis-
tributed (p < 0:0001). Spearman’s rho test showed a high
correlation between the two methods with a coefficient of r
= 0:9998 (p < 0:0001).
The coefficient of determination (R2) showed that the
relation between the expected viral copies (RT-qPCR) and
the measured ones (RT-ddPCR) was linear (R2 = 1:00) and
the slope of the fitted line was 0.91. This regression coefficient
indicates that RT-ddPCR detects 9% less viral copies than
expected. A more accurate estimate of this bias has been
obtained by evaluating the accuracy of the method.
The accuracy of the method was assessed analyzing 4 dif-
ferent concentrations with 10 replicates each. The accuracy
was expressed as the coefficient of variation (CV). For molec-
ular biology assays, CV values are accepted when they are less
than 30% [20]. The results showed that our workflow has a
high level of accuracy, with CV < 30% for all the tested dilu-
tions. The data are summarized in Table 4.
Finally, the precision evaluation data are presented in
Table 5. The repeatability and intermediate precision have
been grouped for each test and analyzed with a unidirectional
analysis of the variance (ANOVA). The coefficient of varia-
tion for both parameters was <25% for all dilutions analyzed.
4. Discussion
The SARS-CoV-2 pandemic posed a major challenge for
national and local public health laboratories, which had to
be reorganized very quickly to identify infected individuals
as soon as possible to enable the development of containment
strategies to prevent the spread of the virus. According to the
World Health Organization (WHO) and Chinese Center for
Disease Control and Prevention (CDC), the current gold
standard for the diagnosis of SARS-CoV-2 infection is based
on the quantitative reverse transcription-PCR PCR (RT-
qPCR) [19], because it has great scalability, it is fast, and it
is fairly inexpensive. On the other hand, qPCR results in
low precision and accuracy assessing samples with a low viral
load, with a sensitivity reported to vary from 30% to 60%
depending on the assay [21–24].
Since January 2020, several assays have been proposed for
the accurate detection of viral RNA in samples of patient with
COVID-19. In this study, we compared the first six published
assays to assess their detection performance (in terms of sen-
sitivity and specificity) using samples collected during the
first wave of the outbreak in Italy. The results showed that
there are substantial differences in the ability to correctly
identify weakly positive samples. Moreover, most of these
assays showed a high LoQ, which makes them unsuitable
for diagnostic purposes. For all these reasons, we validated
our RT-ddPCR workflow using primers and probes for the
envelope gene (E-gene), since it was able to discriminate
10.3 copies of the E-gene of SARS-CoV-2 from the back-
ground, with high sensitivity and specificity (90% and
100%, respectively). Experiments evaluating the SARS-
CoV-2 detection rate in 60 patient samples showed a high
correlation between RT-ddPCR and RT-qPCR. However,
since a high correlation does not necessarily imply that there
is a good agreement between the two methods, we performed
a Bland-Altman test. The bias between the two methods was
0.1683 and almost all measured points were within the 95%
agreement. Taken together, our data suggest that both RT-
ddPCR and RT-qPCR can be used for the detection of
SARS-CoV-2 RNA. Despite that the two methods showed
good agreement and correlation, RT-ddPCR demonstrated
a higher level of accuracy and precision, especially at low
concentration, i.e., approaching the LoQ. Moreover, it pro-
vides an absolute measurement of viral copies without the
need to set the threshold level for RT-qPCR. Since precision
is a key feature in diagnostic procedures, to further
Table 2: Estimated Limit of Blank (LoB), Limit of Detection (LoD),
and Limit of Quantification (LoQ) according to the guidelines of the
International Conference on Harmonisation (ICH) [27].
Target MeanNTC SDNTC LOB LOD LOQ
E gene 0.54 0.98 2.1 7 10.3
N gene 0.75 2.02 4.1 13 21
RdRP gene 2.16 2.12 5.7 19.1 23.4
N2 gene 1.09 1.34 3.3 11 14.5
N3 gene 2.90 2.58 7.1 24.3 28.7
Table 3: Specificity and sensitivity for SARS-CoV-2 assays tested on
30 patient samples.







characterize the advantages of our workflow, we calculated
repeatability and intermediate precision by testing three dif-
ferent dilutions of a positive sample every day for three con-
secutive days. The coefficient of variation (CV) was less than
30% in both inter- and intraday measurements indicating
that there was no significant difference in results between
evaluations.
Unfortunately, all that glisters is not gold. Sample prepa-
ration, droplet generation, and detection take a long time and
increase the investigation time. In addition, samples with a
high viral titer undergo an underestimation of the actual con-
centration of the nucleic acid, as the droplets are saturated,
and the costs of ddPCR are currently higher in comparison
with RT-qPCR.
Indeed, in the last few months, several works have under-
lined the benefits of using the RT-ddPCR for the analysis of
samples with a low SARS-CoV-2 load or derived from
patient’s saliva, comparing both different platforms (i.e.,
QX200 system from Bio-Rad, TD-1 system from Targetin-
gOne, or Naica system from Stilla Technologies) and using
different available kits [21–23, 25, 26]. Despite the diverse
approaches, all of them are in agreement with our data in
considering RT-ddPCR a highly robust technique for
SARS-CoV-2 detection in clinical applications, to be pre-
ferred during patients’ follow-up, as the monitoring of the
correct viral load is essential to contain the infections.
In summary, despite the limitations, RT-ddPCR is a suit-
able, precise, sensitive, and accurate method for the detection
of SARS-CoV-2 RNA, which should be preferred not in mass
screening (i.e., exponential phase of the pandemic) but when
the correct detection of infected subjects would prevent the
possibility of a further wave of infection. We have validated
a workflow based on the detection of the E gene, which allows
to detect as low as 10.3 viral copies. The workflow described
in this work is in fact aimed at reducing false negatives, with
the possibility of evaluating subjects with a low viral load that
would remain undetectable to mass screening with qPCR or
accurately tracking the patient viral load before discharging.
Data Availability
The data used to support the findings of this study are
included within the article.
Disclosure
Parts of this manuscript were presented at the Pathobiology
for Investigators, Students, and Academicians (PISA) 2020
congress (Abstract A051; p:S16).
Conflicts of Interest
The authors declare no conflicts of interest.
Authors’ Contributions
CM, AC, and SM conceptualized the study; CM and AC per-
formed all the experiments and critically contributed to the
interpretation of the results; CM drafted the manuscript;
BM and CM revised the statistical analysis; SM, CP, GD,





































Figure 1: Agreement between RT-qPCR and RT-ddPCR in SARS-CoV-2 RNA detection. (a) Bland-Altman plots representing the agreement
between RT-qPCR and RT-ddPCR. Dotted lines represent the upper limit of 95% agreement, the bias, and the lower limit of 95% agreement.
(b) Boxplot showing log10 of copies of SARS-CoV-2 RNA evaluated with both RT-qPCR and RT-ddPCR. p > 0:05 (ns) by Mann–Whitney U
test.
Table 4: Accuracy of SARS-CoV-2 detection by RT-ddPCR using
the E gene assay.
Analyte (%) Mean (copies) SD (copies) CV%
0.1 238.6 24.3 10.2
0.04 87.9 14.9 16.9
0.02 42.4 7.4 17.3
0.01 26.8 6.5 24.4






CV% p value CV% SD (copies)
100 5.6 0.980 1.5 0.1180
1 3.3 0.7404 0.6 0.0653
0.1 19.6 0.498 12.5 0.0646
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Supplementary Materials
Supplementary Table 1: raw data of the 30 positive samples
used to assess the agreement between RT-qPCR and RT-
ddPCR. (Supplementary Materials)
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